Cormorant Asset Management, LP — SEC insider filings
SEC reporting owner CIK 1583977. 59 insider filings on record with FilingPulse; latest filed 2026-11-02.
Transaction summary — filings shown
Covers the 50 most recent of 59 filings on record, filed 2021-06-30 to 2026-11-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 97 legs across 32 filings — 26,161,680 shares, $394,145,201 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 25 legs across 10 filings — 19,459,827 shares, $67,002,758 total (shares × price as filed on priced legs).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 38.
- Largest priced transaction: purchase of 3,376,646 shares @ $11.27 ($38,053,112) in Ambrx Biopharma Inc., filed 2023-04-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Ambrx Biopharma Inc. (AMAM) | 10% owner | 4 | 11 legs · 10,965,823 sh · $114,106,979 | — | — |
| EyePoint, Inc. (EYPT) | — | 6 | 24 legs · 4,794,057 sh · $89,496,413 | 1 leg · 60,000 sh · $942,240 | — |
| MoonLake Immunotherapeutics (MLTX) | — | 3 | 4 legs · 352,051 sh · $20,324,640 | 5 legs · 6,499,978 sh · $46,868,184 | — |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | — | 6 | 31 legs · 1,932,632 sh · $53,693,261 | 2 legs · 455,029 sh · $2,086,767 | — |
| Erasca, Inc. (ERAS) | Director | 4 | 3 legs · 1,565,384 sh · $19,199,996 | — | 5 |
| BRIGHT MINDS BIOSCIENCES INC. (DRUG) | — | 3 | 12 legs · 606,922 sh · $7,234,370 | 1 leg · 109,331 sh · $9,785,124 | — |
| Immuneering Corp (IMRX) | 10% owner | 3 | 1 leg · 550,000 sh · $8,250,000 | 13 legs · 1,309,091 sh · $3,909,184 | 2 |
| Biomea Fusion, Inc. (BMEA) | — | 6 | 1 leg · 400,000 sh · $12,000,000 | — | 4 |
| Monte Rosa Therapeutics, Inc. (GLUE) | — | 1 | 1 leg · 600,000 sh · $11,400,000 | — | 3 |
| Ventyx Biosciences, Inc. (VTYX) | — | 1 | 1 leg · 625,000 sh · $10,000,000 | — | 3 |
+12 more issuers among the filings shown — every filing appears in the table below.
Insider filings — Cormorant Asset Management, LP
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-02 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Cormorant Global Healthcare Master Fund, LP, Chen Bihua | Sale (S): 425,000 @ $4.10 | EDGAR |
| 2026-08-10 | 4 | BlossomHill Therapeutics, Inc. (BLSM) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund V LP, Cormorant Private Healthcare Fund VI, LP | Conversion (C): 1,599,993 · Conversion (C): 1,701,541 · Purchase (P): 312,500 @ $16 · Grant/award (A): 23,904 (derivative) @ $0 · Conversion (C): 1,599,993 (derivative) · Conversion (C): 1,701,541 (derivative) | EDGAR |
| 2026-04-30 | 4 | BRIGHT MINDS BIOSCIENCES INC. (DRUG) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP | Sale (S): 109,331 @ $89.50 | EDGAR |
| 2025-12-15 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Cormorant Global Healthcare Master Fund, LP, Chen Bihua | Sale (S): 30,029 @ $11.46 | EDGAR |
| 2025-12-08 | 4 | EyePoint, Inc. (EYPT) jointly with Cormorant Global Healthcare Master Fund, LP, Chen Bihua | Sale (S): 60,000 @ $15.70 | EDGAR |
| 2025-10-01 | 4 | MoonLake Immunotherapeutics (MLTX) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund IV LP | Sale (S): 70,748 @ $9.38 · Sale (S): 232,460 @ $8.40 · Sale (S): 3,390,943 @ $7.58 · Sale (S): 2,800,000 @ $6.61 · Sale (S): 5,827 @ $6.96 | EDGAR |
| 2025-08-01 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Holdings only — no transactions reported | EDGAR |
| 2025-06-13 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Grant/award (A): 91,970 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | OnKure Therapeutics, Inc. (OKUR) jointly with Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund IV LP, Cormorant Private Healthcare Fund V LP, Chen Bihua | Sale (S): 1,813,439 @ $1.85 | EDGAR |
| 2025-05-14 | 4 | OnKure Therapeutics, Inc. (OKUR) jointly with Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund IV LP, Cormorant Private Healthcare Fund V LP, Chen Bihua | Sale (S): 24,300 @ $1.99 | EDGAR |
| 2025-02-19 | 4 | Aardvark Therapeutics, Inc. (AARD) jointly with Chen Bihua | Conversion (C): 800,189 · Purchase (P): 187,500 @ $16 · Conversion (C): 6,780,810 (derivative) | EDGAR |
| 2024-11-06 | 4 | BRIGHT MINDS BIOSCIENCES INC. (DRUG) jointly with Chen Bihua | Purchase (P): 184,331 @ $21.70 | EDGAR |
| 2024-10-17 | 4 | BRIGHT MINDS BIOSCIENCES INC. (DRUG) jointly with Cormorant Global Healthcare Master Fund, LP, Chen Bihua | Purchase (P): 238,097 @ $4.53 · Purchase (P): 63,173 @ $5.92 · Purchase (P): 33,343 @ $6.42 · Purchase (P): 8,900 @ $7.31 · Purchase (P): 2,600 @ $8.80 · Purchase (P): 2,700 @ $9.26 · +5 more | EDGAR |
| 2024-10-01 | 4 | BioAge Labs, Inc. (BIOA) jointly with Cormorant Private Healthcare Fund V LP, Chen Bihua, Cormorant Private Healthcare Fund IV LP | Conversion (C): 1,179,529 · Purchase (P): 450,000 @ $18 · Conversion (C): 5,263,772 (derivative) | EDGAR |
| 2024-09-24 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP | Purchase (P): 45,085 @ $17.48 · Purchase (P): 25,943 @ $18.36 · Purchase (P): 66,088 @ $19.61 · Purchase (P): 139,551 @ $20.42 · Purchase (P): 47,564 @ $21.47 · Purchase (P): 25,769 @ $22.23 | EDGAR |
| 2024-06-13 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Grant/award (A): 51,025 (derivative) @ $0 | EDGAR |
| 2024-05-08 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP | Purchase (P): 642,847 @ $11.70 · Purchase (P): 207,153 @ $12.36 | EDGAR |
| 2024-04-22 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP | Purchase (P): 395,244 @ $17.62 · Purchase (P): 186,521 @ $18.90 | EDGAR |
| 2024-04-03 | 4 | Immuneering Corp (IMRX) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Sale (S): 100 @ $3.07 · Sale (S): 300 @ $3.06 · Sale (S): 100 @ $3.05 · Sale (S): 600 @ $3.03 · Sale (S): 10 @ $3.01 · Sale (S): 10 @ $2.98 · +2 more | EDGAR |
| 2024-03-18 | 4 | Immuneering Corp (IMRX) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Sale (S): 345,266 @ $3.23 · Sale (S): 98,570 @ $4.25 · Sale (S): 54,215 @ $5.37 · Sale (S): 11,040 @ $5.97 · Sale (S): 400,000 @ $2.14 | EDGAR |
| 2024-03-11 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP | Purchase (P): 46,799 @ $37.82 · Purchase (P): 10,736 @ $39.13 · Purchase (P): 90,325 @ $39.99 · Purchase (P): 102,140 @ $41.23 · Purchase (P): 29,342 @ $41.23 · Purchase (P): 24,983 @ $42.25 · +4 more | EDGAR |
| 2024-02-06 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Cormorant Global Healthcare Master Fund, LP, Chen Bihua | Purchase (P): 750,000 @ $19 | EDGAR |
| 2024-01-30 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Cormorant Global Healthcare Master Fund, LP, Chen Bihua | Purchase (P): 14,388 @ $25.73 · Purchase (P): 15,243 @ $26.66 · Purchase (P): 36,747 @ $27.70 · Purchase (P): 31,028 @ $28.82 · Purchase (P): 29,244 @ $29.42 · Purchase (P): 2,654 @ $31 · +8 more | EDGAR |
| 2024-01-11 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP | Purchase (P): 105,000 @ $21.32 · Purchase (P): 750,000 @ $19.75 | EDGAR |
| 2023-12-12 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP | Purchase (P): 588,235 @ $17 | EDGAR |
| 2023-12-06 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP | Purchase (P): 321,259 @ $18.80 · Purchase (P): 945,664 @ $19.88 · Purchase (P): 122,625 @ $20.62 · Purchase (P): 79,805 @ $21.87 · Purchase (P): 28,090 @ $22.80 · Purchase (P): 37,081 @ $24.01 · +11 more | EDGAR |
| 2023-10-25 | 4 | Ambrx Biopharma, Inc. (AMAM) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Purchase (P): 1,307,311 @ $6.99 | EDGAR |
| 2023-10-10 | 4 | MoonLake Immunotherapeutics (MLTX) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund IV LP | Purchase (P): 58,839 @ $59.90 | EDGAR |
| 2023-10-04 | 4 | MoonLake Immunotherapeutics (MLTX) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund IV LP | Purchase (P): 74,911 @ $57.37 · Purchase (P): 150,487 @ $57.25 · Purchase (P): 67,814 @ $57.32 | EDGAR |
| 2023-09-19 | 4 | Ambrx Biopharma Inc. (AMAM) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Purchase (P): 1,401,505 @ $9.05 · Purchase (P): 751,233 @ $9.24 | EDGAR |
| 2023-07-24 | 4 | GreenLight Biosciences Holdings, PBC (GRNA) jointly with Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund II, LP, Chen Bihua | Sale (S): 9,188,659 @ $0 | EDGAR |
| 2023-06-26 | 4 | Erasca, Inc. (ERAS) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund II, LP | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Grant/award (A): 6,989 (derivative) @ $0 | EDGAR |
| 2023-04-20 | 4 | Ambrx Biopharma Inc. (AMAM) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Purchase (P): 3,376,646 @ $11.27 · Purchase (P): 951,909 @ $11.15 · Purchase (P): 886,634 @ $11.60 | EDGAR |
| 2023-04-17 | 4 | Ambrx Biopharma Inc. (AMAM) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Purchase (P): 1,193,808 @ $9.16 · Purchase (P): 841,967 @ $9.96 · Purchase (P): 562,121 @ $10.67 | EDGAR |
| 2023-04-03 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Purchase (P): 400,000 @ $30 | EDGAR |
| 2023-03-16 | 4 | Ambrx Biopharma Inc. (AMAM) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Purchase (P): 250,000 @ $9.95 · Purchase (P): 250,000 @ $10.60 · Purchase (P): 500,000 @ $10.15 | EDGAR |
| 2022-12-21 | 4/A | Erasca, Inc. (ERAS) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund II, LP | Purchase (P): 307,692 @ $6.50 | EDGAR |
| 2022-12-20 | 4 | Erasca, Inc. (ERAS) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund II, LP | Purchase (P): 307,692 @ $6.50 | EDGAR |
| 2022-06-24 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Grant/award (A): 23,867 (derivative) @ $0 | EDGAR |
| 2022-01-13 | 4 | Vigil Neuroscience, Inc. (VIGL) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund IV LP | Conversion (C): 616,786 · Conversion (C): 616,786 (derivative) | EDGAR |
| 2021-10-27 | 4 | Ventyx Biosciences, Inc. (VTYX) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Conversion (C): 785,303 · Purchase (P): 625,000 @ $16 · Conversion (C): 548,288 (derivative) · Conversion (C): 237,015 (derivative) | EDGAR |
| 2021-10-15 | 4 | Pyxis Oncology, Inc. (PYXS) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Conversion (C): 668,854 · Purchase (P): 450,000 @ $16 · Conversion (C): 668,854 (derivative) | EDGAR |
| 2021-09-21 | 4 | Tyra Biosciences, Inc. (TYRA) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Conversion (C): 757,432 · Purchase (P): 312,500 @ $16 · Conversion (C): 757,432 (derivative) | EDGAR |
| 2021-08-05 | 4 | Immuneering Corp (IMRX) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Conversion (C): 1,702,628 · Purchase (P): 550,000 @ $15 · Conversion (C): 1,702,628 (derivative) | EDGAR |
| 2021-08-04 | 4 | Icosavax, Inc. (ICVX) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Conversion (C): 426,393 · Conversion (C): 426,393 (derivative) | EDGAR |
| 2021-07-22 | 4 | Erasca, Inc. (ERAS) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund II, LP | Conversion (C): 9,555,553 · Purchase (P): 950,000 @ $16 · Conversion (C): 4,000,000 (derivative) · Conversion (C): 4,166,666 (derivative) · Conversion (C): 1,388,887 (derivative) | EDGAR |
| 2021-07-07 | 4 | Aerovate Therapeutics, Inc. (AVTE) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund II, LP | Conversion (C): 1,530,691 · Purchase (P): 500,000 @ $14 · Conversion (C): 1,530,691 (derivative) | EDGAR |
| 2021-07-01 | 4 | Elevation Oncology, Inc. (ELEV) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Conversion (C): 1,983,168 · Purchase (P): 250,000 @ $16 · Conversion (C): 1,983,168 (derivative) | EDGAR |
| 2021-06-30 | 4 | Monte Rosa Therapeutics, Inc. (GLUE) jointly with Chen Bihua, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund II, LP | Conversion (C): 2,602,200 · Purchase (P): 600,000 @ $19 · Conversion (C): 2,124,343 (derivative) · Conversion (C): 477,857 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1583977 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs